Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy ...
A male in his 50s presented with profound leucocytosis, systemic symptoms and marked hepatosplenomegaly. Initial workup with peripheral blood flow cytometry suggested T-cell prolymphocytic leukaemia ...
Highlighting Positive Results in Comparison to Valchlor(R) and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...
Highlighting Positive Results in Comparison to Valchlor® and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: ...
A simple blood test could speed up diagnosis and improve outcomes for children with Africa's most common childhood cancer. In a study published in ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) ...
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab) ...
The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.
The FDA has approved nivolumab (Opdivo) plus doxorubicin, vinblastine, and dacarbazine (AVD) for the treatment of adult and pediatric patients age 12 and older with treatment-naiv ...
The FDA has approved the combination of nivolumab plus chemotherapy as first-line treatment for certain patients with stage ...
FDA approval extends nivolumab into first-line stage III/IV cHL in adults and pediatrics, following priority review of the ...
Frontline nivolumab plus AVD reduced risk of progression or death by 58% versus brentuximab vedotin plus AVD (PFS HR, 0.42) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results